(UoM-Melb) Correlating brain and systemic inflammation with peripheral and central neurodegeneration in mice and humans

Post-stroke dementia occurs in around 30% of stroke survivors, impacting significantly on quality of life and also causing a high burden of disease. There are no current effective treatments to prevent or slow the progression of post-stroke dementia and the underlying mechanisms remain unclear.

In experimental models and clinical studies of patients experiencing stroke, immune/inflammatory changes are observed immediately after the event, both in the brain and in the blood. These changes have been proposed as a therapeutic target. There is evidence of long term immune/inflammatory changes post-stroke, which have been suggested as important contributors to the development of post- stroke dementia, and other long-term complications including neurodegeneration in other areas of the body, including the cornea. The cornea is a highly accessible tissue that can be imaged using a non-invasive clinical microscope, which enables direct observation of individual sensory nerve axons, and is used as a surrogate marker of peripheral nerve health. Most experimental models of stroke-induced pathology have focused on the inflammatory response in the brain, which is to be expected given the location of stroke trauma. Few studies have considered how stroke affects the activation of immune cells and inflammatory markers in the systemic circulation (i.e. blood), and other tissues that harbour dense networks of sensory nerves, which belong to the peripheral nervous system. Understanding how stroke can lead to widespread inflammatory changes in the circulation, and how it contributes to peripheral nerve pathology, is important to identify possible targets for therapies aimed at reducing the risk of post-stroke complications.

This project will use an experimental model of stroke to longitudinally measure inflammatory markers and immune cell activation in the brain, blood and eye at acute and long-term timepoints after stroke. The severity of inflammation will be correlated with cognitive function. This project will also include a clinical study of corneal nerve changes and tear neuropeptides (proteins present in tears that indicate nerve health) in stroke patients, to assess whether the cornea can serve as a useful tissue to determine nerve health and immune activation more broadly in post-stroke patients. A wide range of techniques will be used including clinical corneal imaging and tear fluid protein assays in humans, and high-dimensional multi-colour flow cytometry, blood brain barrier integrity and cognitive function testing in experimental models.

Supervisory Team:

• Prof Stuart Allan, Prof Craig Smith (The University of Manchester)
• Dr Holly Chinnery, A/Prof Laura Downie, Prof Amy Brodtmann (The University of Melbourne)

Entry Requirements

Candidates will need to meet the minimum entry requirements of both Universities to be accepted. You'll also need to be registered at both institutions for the duration of the programme. The entry criteria for the University of Melbourne can be found on their how to apply webpage. Candidates are expected to hold (or be about to obtain) a minimum upper second class honours degree (or equivalent) in a related area/subject to meet the entry criteria for the University of Manchester.

How to Apply

For further information about applying for one of the Manchester based projects can be found on our how to apply page. Candidates looking to apply for a Manchester-based project are encouraged to contact the named Manchester supervisor for an initial discussion before submitting an official application form. You MUST also submit an online application form - choose PhD Cancer Sciences.

Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website https://www.bmh.manchester.ac.uk/study/research/apply/equality-diversity-inclusion/